SLC5A2 and chronic kidney disease: Robust evidence from landmark clinical trials and real-world data has demonstrated that SGLT-2 inhibitors significantly slow the progression of CKD, reduce albuminuria, and lower the risk of cardiovascular events (20, 83, 84).